Search for content, post, videos

Positive results for Novo Nordisk’s Saxenda

novo nordisk

Novo Nordisk’s Saxenda demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo.

New data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity – Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016). The three-year part of the trial (n=2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline) data demonstrated that 160 weeks of treatment with Saxenda® (liraglutide 3 mg) (n=1,505) in combination with a reduced-calorie diet and increased physical activity resulted in significant improvements in cardiometabolic risk factors (such as blood pressure and cholesterol) compared with placebo (reduced-calorie diet and increased physical activity alone) (n=749).

Leave a Reply

Your email address will not be published. Required fields are marked *

5 × 5 =